MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/14/2026

1. IBM
2. JPM
3. TREX
4. WFC
5. ERAS
6. BAC
7. SPY
8. SPCX
9. SPRO
10. CLSK

Go back to MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
(NASDAQ: MYOK) Delayed: 224.91 --0 (-0%)
Previous Close $224.91    52 Week High $22.83 
Open $0.47    52 Week Low $6.24 
Day High $224.91    P/E N/A 
Day Low $224.91    EPS $0.00 
Volume 350